These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11818165)

  • 1. Mucosal immunity in mice immunized with HIV-1 peptide conjugated to Brucella abortus.
    Golding B; Eller N; Levy L; Beining P; Inman J; Matthews N; Scott DE; Golding H
    Vaccine; 2002 Jan; 20(9-10):1445-50. PubMed ID: 11818165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brucella abortus conjugated with a peptide derived from the V3 loop of human immunodeficiency virus (HIV) type 1 induces HIV-specific cytotoxic T-cell responses in normal and in CD4+ cell-depleted BALB/c mice.
    Lapham C; Golding B; Inman J; Blackburn R; Manischewitz J; Highet P; Golding H
    J Virol; 1996 May; 70(5):3084-92. PubMed ID: 8627787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brucella abortus conjugated with a gp120 or V3 loop peptide derived from human immunodeficiency virus (HIV) type 1 induces neutralizing anti-HIV antibodies, and the V3-B. abortus conjugate is effective even after CD4+ T-cell depletion.
    Golding B; Inman J; Highet P; Blackburn R; Manischewitz J; Blyveis N; Angus RD; Golding H
    J Virol; 1995 Jun; 69(6):3299-307. PubMed ID: 7745677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV peptide conjugated to heat-killed bacteria promotes antiviral responses in immunodeficient mice.
    Scott DE; Golding H; Huang LY; Inman J; Golding B
    AIDS Res Hum Retroviruses; 1998 Sep; 14(14):1263-9. PubMed ID: 9764910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic and mucosal immunity in rhesus macaques immunized with HIV-1 peptide and gp120 conjugated to Brucella abortus.
    Eller N; Golding H; Inoue S; Beining P; Inman J; Matthews N; Scott DE; Golding B
    J Med Primatol; 2004 Aug; 33(4):167-74. PubMed ID: 15271066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production of a novel antigen by conjugation of HIV-1 to Brucella abortus: studies of immunogenicity, isotype analysis, T-cell dependency, and syncytia inhibition.
    Golding B; Golding H; Preston S; Hernandez D; Beining PR; Manischewitz J; Harvath L; Blackburn R; Lizzio E; Hoffman T
    AIDS Res Hum Retroviruses; 1991 May; 7(5):435-46. PubMed ID: 1678617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
    Staats HF; Nichols WG; Palker TJ
    J Immunol; 1996 Jul; 157(1):462-72. PubMed ID: 8683152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. M cell DNA vaccination for CTL immunity to HIV.
    Wang X; Hone DM; Haddad A; Shata MT; Pascual DW
    J Immunol; 2003 Nov; 171(9):4717-25. PubMed ID: 14568947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation.
    Buonaguro L; Visciano ML; Tornesello ML; Tagliamonte M; Biryahwaho B; Buonaguro FM
    J Virol; 2005 Jun; 79(11):7059-67. PubMed ID: 15890945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.
    Nehete PN; Chitta S; Hossain MM; Hill L; Bernacky BJ; Baze W; Arlinghaus RB; Sastry KJ
    Vaccine; 2001 Dec; 20(5-6):813-25. PubMed ID: 11738745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of humoral and cellular immune responses in mice by HIV-derived infectious pseudovirions.
    Racek T; Jármy G; Jassoy C
    AIDS Res Hum Retroviruses; 2006 Nov; 22(11):1162-6. PubMed ID: 17147504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemagglutinating virus of Japan protein is efficient for induction of CD4+ T-cell response by a hepatitis B core particle-based HIV vaccine.
    Takeda S; Shiosaki K; Kaneda Y; Nakasatomi T; Yoshizaki H; Someya K; Konno Y; Eda Y; Kino Y; Yamamoto N; Honda M
    Clin Immunol; 2004 Jul; 112(1):92-105. PubMed ID: 15207786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses.
    Sakaue G; Hiroi T; Nakagawa Y; Someya K; Iwatani K; Sawa Y; Takahashi H; Honda M; Kunisawa J; Kiyono H
    J Immunol; 2003 Jan; 170(1):495-502. PubMed ID: 12496436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on in vivo induction of HIV-1 envelope-specific cytotoxic T lymphocytes by synthetic peptides from the V3 loop region of HIV-1 IIIB gp 120.
    Nehete PN; Casement KS; Arlinghaus RB; Sastry KJ
    Cell Immunol; 1995 Feb; 160(2):217-23. PubMed ID: 7720083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary results of V3 loop peptide-primary neutralizing domain conjugate phase 1 vaccine trail.
    Rubinstein A; Goldstein H; Pettoello-Mantovani M; Cryz SJ
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S149-53. PubMed ID: 7865291
    [No Abstract]   [Full Text] [Related]  

  • 16. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity.
    Belyakov IM; Moss B; Strober W; Berzofsky JA
    Proc Natl Acad Sci U S A; 1999 Apr; 96(8):4512-7. PubMed ID: 10200293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target.
    Manocha M; Pal PC; Chitralekha KT; Thomas BE; Tripathi V; Gupta SD; Paranjape R; Kulkarni S; Rao DN
    Vaccine; 2005 Dec; 23(48-49):5599-617. PubMed ID: 16099080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity.
    Devito C; Zuber B; Schröder U; Benthin R; Okuda K; Broliden K; Wahren B; Hinkula J
    J Immunol; 2004 Dec; 173(11):7078-89. PubMed ID: 15557206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transgene vaccination using Ulex europaeus agglutinin I (UEA-1) for targeted mucosal immunization against HIV-1 envelope.
    Wang X; Kochetkova I; Haddad A; Hoyt T; Hone DM; Pascual DW
    Vaccine; 2005 May; 23(29):3836-42. PubMed ID: 15893622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity.
    Hinkula J
    Expert Rev Vaccines; 2007 Apr; 6(2):203-12. PubMed ID: 17408370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.